Mydayis

Draft medication scaffold. Needs source pass before publish.

Mydayis belongs to the same stimulant family as Adderall XR, but it’s built to keep releasing later into the day, which is why some people love it and some people feel like it follows them too far into the evening.

The basics

Mydayis comes as an extended release capsule made from mixed amphetamine salts. The label describes it as a once-daily treatment for ADHD in patients age 13 and older. Capsules come in 12.5 mg, 25 mg, 37.5 mg, and 50 mg strengths and are usually taken in the morning on a consistent schedule. You can swallow the capsule whole or open it and sprinkle the contents on applesauce, but you don’t split the dose across the day.1

Side effects that actually matter

The common adverse effects line up with what you’d expect from amphetamine stimulants: insomnia, decreased appetite, weight loss, dry mouth, increased heart rate, nausea, irritability, and anxiety.1 The practical issue is that the long duration can make ordinary stimulant side effects feel harder to outrun. It also carries the usual stimulant cautions around misuse, blood pressure and heart rate, worsening anxiety, and rare psychiatric destabilization in vulnerable patients.1

What makes me reach for it or skip it

I think about Mydayis when someone clearly benefits from amphetamine treatment but keeps losing the second half of the day, especially if they’re patching things together with boosters and still ending up inconsistent. I’m less interested in it when sleep is already shaky, when anxiety is front and center, or when the person has done well on shorter agents that allow more control over timing. The label also matters here: Mydayis is approved for age 13 and older, and younger children had higher exposure and more insomnia and appetite suppression in studies, which is why the product isn’t indicated below that age.1

Whether Mydayis is right for a particular person is the same question it is with any stimulant: does the benefit clear the trade, for this person, at this point in their life.

The duration question: when 16 hours helps and when it doesn’t

Mydayis is unusual among amphetamine formulations because the label puts maximum duration at 16 hours, which is longer than almost anything else on the market. Adderall XR gets most adults through about 8 to 10 hours. Vyvanse extends to 12 or 14 for many people. Mydayis pushes further, and that’s either the point or the problem depending on who’s taking it.

For an adult whose day genuinely runs long, whose ADHD is worst in the evening hours when other stimulants have worn off, or who has consistently found themselves needing a booster dose in the late afternoon and still coming up short, Mydayis can be a better fit than stacking medications. One dose, predictable coverage, no decisions about when to take the second one.

For anyone where sleep is already a concern, evening anxiety is a pattern, or the stimulant effect running into evening would affect things that matter at home, the 16-hour window is a real problem, not a feature. Starting Mydayis and then wondering why sleep quality tanked is a predictable outcome when the drug is still pharmacologically active at bedtime. That’s not individual variation, that’s pharmacokinetics doing exactly what the label says it does.

The practical test is honest accounting of when coverage is actually needed. If the answer is “through about 3pm,” Mydayis is probably more than what’s needed and the extra duration costs sleep and appetite without buying anything useful. If the answer is “I need to function through 7 or 8pm and I’m consistently falling apart in the afternoon on everything I’ve tried,” then 16 hours is a feature worth the tradeoffs.

How Mydayis compares to Adderall XR and Vyvanse

All three are amphetamine-based ADHD treatments. The key differences are duration, pharmacology, and what the pattern looks like across a day.

Adderall XR is mixed amphetamine salts in a bead capsule that delivers half the dose immediately and the other half four hours later. Duration for most adults is 8 to 10 hours. The biphasic delivery gives a noticeable two-pulse effect that some people find helpful and others find too variable. Mydayis uses a triple-bead system with three different release profiles, designed to maintain coverage further into the afternoon and evening than Adderall XR does.

Vyvanse is a different molecule entirely: lisdexamfetamine, a prodrug that gets converted to dextroamphetamine in the bloodstream. The conversion process is what smooths the curve, giving Vyvanse its reputation for a more even rise and fall than immediate release or bead-based amphetamine products. Duration is typically 10 to 14 hours. Vyvanse is also significantly harder to misuse than other amphetamine products because the prodrug mechanism only activates in the bloodstream, not through crushing or snorting.

Mydayis, Adderall XR, and Vyvanse are all schedule II controlled substances with real misuse and diversion potential. The prodrug design of Vyvanse is the clearest pharmacological feature that differentiates it on that dimension. Mydayis and Adderall XR don’t have that protection.

On efficacy: all three work via the same mechanism and there’s no meaningful evidence that one is categorically superior. Individual response varies. Some people find Vyvanse smoother. Some find Mydayis gives coverage that Vyvanse doesn’t reach. Some do best on Adderall XR’s more aggressive early peak. The right choice is often discovered through trying rather than predicted from the pharmacology.

Dosing and titration

Mydayis is approved for ages 13 and up. Starting dose is typically 12.5mg once daily in the morning. Doses are usually adjusted in weekly intervals based on response and tolerability, with the labeled maximum at 50mg per day. Because of the long duration, dose adjustments need more observation time than shorter acting medications: the full effect of a dose change takes several days to stabilize in daily use, and evaluating based on day one or two can mislead both the prescriber and the patient.

Take it consistently in the morning, at roughly the same time each day. High-fat meals delay absorption and can shift when peak coverage arrives, which matters for predicting how the day goes. If you’ve been taking it with a heavy breakfast and switch to empty stomach, expect a change in timing even at the same dose.

One thing that affects amphetamine exposure that most patients don’t know: urinary pH. Acidifying foods and supplements (vitamin C, certain juices in high doses) speed up amphetamine excretion and can shorten duration or reduce efficacy. Alkalinizing agents do the opposite. This usually doesn’t matter day to day, but if the medication is working inconsistently and nothing about the dose or timing has changed, what went in around it’s worth examining.

Misuse and diversion context

Mydayis carries the full weight of schedule II classification. It’s a long-acting mixed amphetamine formulation, and amphetamines have a meaningful history of misuse both for recreational purposes and as cognitive performance enhancers among people without ADHD. The 16-hour duration means longer active exposure per dose, which changes the misuse risk profile compared to shorter acting formulations.

In clinical practice, the same conversations apply here that apply to every schedule II stimulant: where are the pills stored, who else has access, what happens when there’s a gap in coverage. These aren’t hostile questions, they’re part of responsible prescribing for any controlled substance. A patient who genuinely has ADHD and is benefiting from treatment is not harmed by those questions. The harm comes from not having them.

What to know before stopping or switching

You don’t taper Mydayis the way you’d taper an antidepressant or benzodiazepine, but you still want a plan. A sudden stop may leave someone tired, irritable, unfocused, or flat for a bit, especially if the dose was doing a lot of work. Switching to another stimulant is usually about matching duration and potency, not just swapping names on a bottle. Because food timing and urinary pH can shift amphetamine exposure, and because a high-fat meal can delay absorption, you also want the before-and-after comparison to be clean before deciding the medication failed.1

Sources

1. DailyMed. Mydayis prescribing information. Updated April 2026. Accessed June 6, 2026. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=141a7970-3f06-44ea-9ab7-aeece2c085fc

2. Weisler RH, Greenbaum M, Arnold V, et al. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study. CNS Drugs. 2017;31(8):685-697. PMID 28712074. https://pubmed.ncbi.nlm.nih.gov/28712074/

3. Spencer TJ, Adler LA, Weisler RH, Youcha SH. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry. 2008;69(9):1437-1448. PMID 19012813. https://pubmed.ncbi.nlm.nih.gov/19012813/